Plasmonic Gold Chip for Multiplexed Detection of Ovarian Cancer Biomarker in Urine

Abstract

Human epididymal protein 4(HE4), carbohydrate antigen 125 (CA125) and osteopontin(OPN) are three key biomarkers in detecting ovarian cancer. To explore the diagnosis value of combined detection of these three biomarkers for ovarian cancer, we developed a multiplexed assay on a plasmonic gold(pGOLD) platform for measuring HE4, CA125 and OPN in urine. The receiver operator characteristic(ROC) curve was drawn, and the diagnosis values of each biomarker alone or in combination for ovarian cancer were evaluated. In the analysis to distinguish ovarian cancer from other gynecological cancers, ovarian cysts and healthy people, the sensitivities of HE4, CA125 and OPN were 72.55%, 52.82% and 68.63%, the specificity values were 95.06%, 87.65% and 90.12%, while the areas under the curve(AUC) were 0.85, 0.75 and 0.77, respectively. The sensitivity and specificity for combination detection of the three markers were 90.20% and 80.25%. The detection methods of HE4, CA125 and OPN based on plasma fluorescence enhanced chip showed good analytic and diagnostic performance, and provided a non-invasive method for the diagnosis of ovarian cancer.

Keywords

Plasmonic gold chip / Urine / Ovarian cancer / Multiplexed detection

References

[1] Siegel R L, Miller K D, Jemal A. CA Cancer J. Clin., 2019, 69: 7.

[2] Jayson G C, Kohn E C, Kitchener H C, Ledermann J A. The Lancet, 2014, 384: 1376.

[3] Earle C C, Schrag D, Neville B A, Yabroff K R, Topor M, Fahey A, Trimble E L, Bodurka D C, Bristow R E, Carney M, Warren J L. JNCI: Journal of the National Cancer Institute, 200, 98: 172.

[4] Paulsen T, Kjærheim K, Kærn J, Tretli S, Trope C. International Journal of Gynecologic Cancer, 200, 16: 11.

[5] Carney M E, Lancaster J M, Ford C, Tsodikov A, Wiggins C L. Gynecol Oncol., 2002, 84: 36.

[6] Pei C, Liu C, Wang Y, Cheng D, Li R, Shu W, Zhang C, Hu W, Jin A, Yang Y, Wan J. Angew. Chem. Int. Ed., 2020, 59: 10831.

[7] Su H, Li X, Huang L, Cao J, Zhang M, Vedarethinam V, Di W, Hu Z, Qian K. Adv. Mater., 2021, 33: 2007978.

[8] Samarah L Z, Vertes A. VIEW, 2020, 1: 20200063.

[9] Tabakman S M, Lau L, Robinson J T, Price J, Sherlock S P, Wang H, Zhang B, Chen Z, Tangsombatvisit S, Jarrell J A, Utz P J, Dai H. Nature Communications, 2011, 2: 466.

[10] Zhang B, Yang J, Zou Y, Gong M, Chen H, Hong G, Antaris A L, Li X, Liu C-L, Chen C, Dai H. Chemical Science, 2014, 5: 4070.

[11] Koh B, Li X, Zhang B, Yuan B, Lin Y, Antaris A L, Wan H, Gong M, Yang J, Zhang X, Liang Y, Dai H. Small, 201, 12: 457.

[12] Goodman M T, Howe H L, Tung K H, Hotes J, Miller B A, Coughlin S S, Chen V W. Cancer, 2003, 97: 2676.

[13] Pearl M L, Zhao Q, Yang J, Dong H, Tulley S, Zhang Q, Golightly M, Zucker S, Chen W-T. Gynecol Oncol., 2014, 134: 581.

[14] Hacker N F, Rao A. Best Practice & Research Clinical Obstetrics & Gynaecology, 2017, 41: 71.

[15] Davidson B, Tropé C G. Womens Health, 2014, 10: 519.

[16] Aust S, Pils D. Wien Med Wochenschr, 2014, 164: 479.

[17] Rustin G J S, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M, Thigpen T, du Bois A, Kristensen G, Jakobsen A, Sagae S, Greven K, Parmar M, Friedlander M, Cervantes A, Vermorken J. International Journal of Gynecologic Cancer, 2011, 21: 419.

[18] Clauss A, Lilja H, Lundwall Å. Biochem. J., 2002, 368: 233.

[19] Trudel D, Têtu B, Grégoire J, Plante M, Renaud M-C, Bachvarov D, Dou-ville P, Bairati I. Gynecol Oncol., 2012, 127: 511.

[20] Drapkin R, von Horsten H H, Lin Y, Mok S C, Crum C P, Welch W R, Hecht J L. Cancer Res., 2005, 65: 2162.

[21] Yuan C, Li R, Yan S, Kong B. Clinical Chemistry and Laboratory Medicine (CCLM), 2018, 56: 1026.

[22] Steffensen K D, Waldstrøm M, Brandslund I, Petzold M, Jakobsen A. International Journal of Gynecologic Cancer, 2012, 22: 1474.

[23] Rainczuk A, Condina M, Pelzing M, Dolman S, Rao J, Fairweather N, Jobling T, Stephens A N. J. Proteome. Res., 2013, 12: 4074.

[24] Rosen D G, Wang L, Atkinson J N, Yu Y, Lu K H, Diamandis E P, Hellstrom I, Mok S C, Liu J, Bast R C. Gynecol Oncol., 2005, 99: 267.

[25] Rustin G J S. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 2003, 21: 187s.

[26] Brakora K A, Lee H, Yusuf R, Sullivan L, Harris A, Colella T, Seiden M V. Gynecol Oncol., 2004, 93: 361.

[27] Guan G F. Journal of Medical Forum, 2009, 30: 9.

[28] Han H-F, Yen H-C, Wu H-C, Tan H-Y, Xu W, Jiang H-S, Tsai P-J, Qian K, Wu Y-C, Chen C-C. ACS Applied Materials & Interfaces, 2021, 13: 57036.

[29] Xu W, Wang L, Zhang R, Sun X, Huang L, Su H, Wei X, Chen C-C, Lou J, Dai H, Qian K. Nature Communications, 2020, 11: 1654.

[30] Zhang R, Le B, Xu W, Guo K, Sun X, Su H, Huang L, Huang J, Shen T, Liao T, Liang Y, Zhang J X J, Dai H, Qian K. Small Methods, 2019, 3: 1800474.